🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Citi sets price target on Privia Health stock, cites flexible model

EditorAhmed Abdulazez Abdulkadir
Published 04/22/2024, 06:38 PM
PRVA
-

Monday - Citi has initiated coverage on Privia Health Group Inc (NASDAQ:PRVA) with a Buy rating and a price target set at $25.00. The firm highlights Privia Health's flexible business model as a key advantage, particularly its ability to adapt across various market segments such as Medicare, Medicaid, and Commercial insurance.

According to the analyst, Privia Health's approach allows it to navigate different levels of risk, from fee-for-service to fully capitated models. This adaptability positions the company as a top pick within the value-based care (VBC) sector. The firm likens Privia Health to an "asset manager" of care, capable of shifting risk in response to market conditions.

Privia Health's extensive care provision across all market segments and its strong connections with multi-specialty groups and health systems are seen as significant factors that boost its negotiating power with payors. These relationships are considered to enhance the company's competitive edge.

Despite the robustness of Privia Health's business model, its stock has experienced a decline of approximately 29% over the past year. This downturn is attributed to market perceptions that have grouped Privia Health with capitated primary care providers. However, Citi views the current valuation, which shows Privia Health trading at a 35% discount to its historical levels and at a slight discount to its peers, as an attractive opportunity for investors.

InvestingPro Insights

As Privia Health Group Inc (NASDAQ:PRVA) garners attention with a fresh Buy rating from Citi, real-time data from InvestingPro enhances the narrative. With a market capitalization of $2.15 billion and a significant 22.19% revenue growth over the last twelve months as of Q4 2023, Privia Health indeed reflects the flexibility and growth potential cited by analysts. The company's P/E ratio stands at 91.01, which, when paired with its PEG ratio of 0.28, suggests that its earnings growth could be undervalued relative to its peers.

Two pertinent InvestingPro Tips for Privia Health include the company holding more cash than debt, which provides a solid financial cushion, and the projection that net income is expected to grow this year. These factors, combined with the company trading near its 52-week low, may present a compelling case for investors considering the stock. For those seeking a deeper dive, InvestingPro offers additional tips and metrics, including an analysis of the company's fair value. Prospective investors can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription and explore the full list of 10 additional InvestingPro Tips.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.